Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

mRNA 2416

Next Previous
Drug Profile

mRNA 2416

Alternative Names: mRNA-2416; OX40L mRNA - Moderna Therpeutics

Latest Information Update: 22 Jul 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Moderna Therapeutics
  • Class Antineoplastics; Immunotherapies; RNA
  • Mechanism of Action OX40 ligand stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Lymphoma; Ovarian cancer; Solid tumours

Most Recent Events

  • 07 Jul 2022 Moderna Therapeutics terminates a phase I/II trial in Solid tumours, Ovarian cancer and Lymphoma (Combination therapy, Monotherapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA because the efficacy endpoints were not met for either treatment arm (Intratumoural) (NCT03323398)
  • 05 Aug 2021 Discontinued - Phase-I/II for Lymphoma (Combination therapy, Late-stage disease, Refractory metastatic disease, Second-line therapy or greater) in USA (Intratumoural)
  • 05 Aug 2021 Discontinued - Phase-I/II for Lymphoma (Late-stage disease, Monotherapy, Refractory metastatic disease, Second-line therapy or greater) in USA (Intratumoural)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top